[{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/key-papers/solid-tumours.ts","type":"changed","fields":[{"field":"summary","before":"\"Multi-arm, multi-stage platform trial. This comparison randomised 1,917 men with newly diagnosed locally advanced or metastatic prostate cancer starting androgen deprivation therapy (ADT) to ADT alone or ADT plus abi...","after":"\"STAMPEDE is a multi-arm, multi-stage platform trial. This comparison randomised 1,917 men with newly diagnosed locally advanced or metastatic prostate cancer starting androgen deprivation therapy (ADT) to ADT alone o..."}]},{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/","commit":"0946997703","date":"2026-09-08","author":"Jude Gomila","message":"Key papers: solid tumours","file":"src/data/key-papers/solid-tumours.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"tldr"},{"field":"summary"},{"field":"journal"},{"field":"year"},{"field":"doi"},{"field":"authors"},{"field":"paperType"},{"field":"participants"},{"field":"changedPractice"},{"field":"findings"},{"field":"whatItMeans"},{"field":"caveats"},{"field":"links"},{"field":"cancers"},{"field":"targets"},{"field":"technologies"},{"field":"terms"},{"field":"companies"},{"field":"institutions"},{"field":"people"},{"field":"bottlenecks"}]}]